This excerpt taken from the EYE 8-K filed Jul 13, 2005.
Research and Development and Regulatory
VISXs research efforts have been the primary source of its products. VISX incurred research and development expenses, including clinical trial expenses, of $21.4 million in 2004, $18.6 million in 2003, and $18.7 million in 2002. Licensed technology developed by outside parties is an additional source of potential
products. For example, VISX continued funding the early stage research at Stanford University for future treatments for age-related macular degeneration.